US 8263572
RNAi modulation of RSV and therapeutic uses thereof
granted A61KA61K31/713A61K9/0078
Quick answer
US patent 8263572 (RNAi modulation of RSV and therapeutic uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K31/713, A61K9/0078, A61P, A61P11/00